Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron.
Dickinson J, Lewand M, Sawamoto T, Krauwinkel W, Schaddelee M, Keirns J, Kerbusch V, Moy S, Meijer J, Kowalski D, Morton R, Lasseter K, Riff D, Kupčová V, van Gelderen M.
Dickinson J, et al. Among authors: sawamoto t.
Clin Drug Investig. 2013 Jan;33(1):11-23. doi: 10.1007/s40261-012-0031-3.
Clin Drug Investig. 2013.
PMID: 23208320
Clinical Trial.